Drug discovery and development partnership company Evotec has deployed the Genedata Screener software platform for support of its broad assay and screening portfolio.
This broad adoption of Genedata Screener helps Evotec to drive its research with standardized assay data of the highest quality, and to simplify collaborative workflows on projects across sites and with biopharma customers globally.
Dr Dirk Ullmann, global head of drug discovery services at Evotec commented: ‘We have been working closely with Genedata scientists who have displayed a deep understanding of our R&D processes and workflows. We have enjoyed a very positive experience with Genedata Screener and seen a significant evolution of the software over that period to continually address our needs and those of our partners in the biopharma industry. These experiences have prompted us to deploy Genedata Screener globally to harmonise our data analysis workflow internally, and we look forward to the continued expansion of our successful relationship with Genedata.’
Evotec has now adopted Genedata Screener for all assay types, in particular for the analysis of its modern assay portfolio such as automated patch clamp screening, quantitative reverse transcription PCR, and high content screening, and to support its high throughput screening, hit-to-lead, compound profiling and safety testing programs.
Following the global roll-out, Evotec is able to switch from its legacy analysis tools and systems to the harmonised, technologically advanced system provided by Genedata Screener, with its capacity to analyse newer assay types, its centralised cost-effective global deployment, and Genedata’s commitment to continuous development in support of increasing laboratory automation and digitalisation. Standardising on Genedata Screener enables advanced process automation and workflow digitalisation, including workflow cost savings for Evotec.
‘We are excited about our long-term collaboration with Evotec and our goal to automate complex R&D workflows, enabling Evotec to accelerate their research programs,’ noted Dr Othmar Pfannes, CEO of Genedata. ‘We are working towards a fully integrated analysis workflow system that produces rapid results that can be summarised and reported at the click of a single button. By rolling out Genedata Screener across their research sites, Evotec validates our joint vision of making biopharma R&D more efficient.’
